In 2023, Advagen Pharma Europe OÜ had revenue of 354.7 thousand EUR and profit of 11.1 thousand EUR. Beneficial owners: Parag Suganchand Sancheti.
| year | 2023Latest |
|---|---|
Revenue | 354,7k € |
Profit | 11,1k € |
Assets | - |
Liabilities | - |
Equity | 6,7k € |
Employees | - |
Overall rating | B+83/100 |
Financial health | 100/100 |
Credit history | 70/100 |
Legal history | 100/100 |
Business activity | 50/100 |
| Overall risk | Low |
No risk flags | |
Possible tax debts | |
Positive profit | |
Incomplete reports | |
| Name, surname | Birth date | Position | Representation rights | Registered | |
|---|---|---|---|---|---|
| - | Authorised representative | - | |||
| - | Board member | - | |||
| - | Board member | - | |||
| - | Board member | - | |||
| - | Board member | - | |||
| - | Board member | - |
Advagen Pharma Europe OÜ is located at Harju maakond, Tallinn, Kesklinna linnaosa, Viru väljak 2, 10111.
In 2023, Advagen Pharma Europe OÜ had revenue of 354 702 EUR and profit of 11 135 EUR. View full financial report →
The beneficial owners of Advagen Pharma Europe OÜ are Parag Suganchand Sancheti. View ownership details →
No, Advagen Pharma Europe OÜ does not have an active VAT number and is not registered as a VAT payer.
Advagen Pharma Europe OÜ was founded on May 15, 2023. The company has been operating for 3 years.
| Indicator | Value | Rank | Comparison | |
|---|---|---|---|---|
Company age | 3 years | 6 - 9 | 22% | |
Net revenue | 354 702,00 € | 2 - 6 | 67% | |
Profit | 11 135,00 € | 1 - 4 | 89% | |
Equity | 6715,00 € | 3 - 7 | 43% | |
Liquidity | 1.00 | - | 25% | |
Profitability | 3.1% | - | 10% | |
Registered capital | 0,01 € | - | 10% |
Annual financial report for 2023.
Registered in the Estonian business register.
| Name, surname | Shares | Ownership rights | |
|---|---|---|---|
| Rubicon Research Limited | - | 100.00% |
| Name, surname | Nationality | Birth date | |
|---|---|---|---|
| Parag Suganchand Sancheti | IN | - |